Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Treatments: Drug: Mavacamten

Study type: Observational

Funder types: Industry

Identifiers

NCT07168655

CV027-1039

Details and patient eligibility

About

The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US

Enrollment: 163 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years at index date
• Prescription of mavacamten for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM)
• ≥ 4 weeks of follow-up after prescription of mavacamten

Exclusion criteria

• Data collection as part of a clinical trial during the study period
• Current participation in a myosin inhibitor clinical trial

Trial design

163 participants in 1 patient group

Participants prescribed mavacamten treatment

Treatment:

Drug: Mavacamten